Stephen Miller, a former Trump White House advisor, stated on Friday that if Donald Trump had stayed president, pharmaceutical firms would have already updated the formulas of Covid-19 vaccinations to prevent the new Omicron strain from being transmitted.
Mr Miller told viewers on a special episode of Fox News’ Hannity that if Mr Trump were still in government, the United States would “already have updated immunizations to cope with the new variations.”
“President Trump sent immunizations to us in record time… and he’d have updates, as well,” he said.
Neither Mr Miller nor the previous president elaborated on how the former president would have permitted vaccine makers to build vaccines for new variations before they were found and virus researchers mapped their genetic sequences.
After sequencing the genetic code of SARS-CoV-2 — the virus that causes Covid-19 — in January 2020, scientists were able to confirm that the virus was responsible for the Covid-19 outbreak in China’s Wuhan Province.
Sandra Lindsey, an intensive care unit nurse in New York City, was the recipient of the first Covid-19 vaccine in the United States outside of a clinical study on December 14, 2020, about a year after the first vaccination was provided in the country.
While the development of an updated vaccine tailored for new variants such as the Omicron variant, which has recently been discovered in South Africa, would take much less time, it is unclear how the identity of the president would factor into the amount of time it would take to develop, manufacture, and test any potential new vaccine candidates.
Pfizer CEO Albert Bourla said at a news conference with President Joe Biden in June that his business may have an updated Covid-19 vaccine available for use within 100 days of the finding of a new “escape variation” that is capable of evading the present vaccination regimens.
The Messenger RNA technology used by vaccines like as those manufactured by Pfizer and Moderna may be readily modified to develop vaccinations for new variations.
Earlier this month, Jacquleline Miller, Moderna senior vice president and head of infectious disease research, told Nature that her company was submitting test cases using vaccines developed to block the Beta and Delta variants of SARS-CoV-2 to the Food and Drug Administration in order to “establish a process” that would allow new variant-specific vaccines to reach the market more quickly.
Are you sick of seeing ads? Well then it's time to get rid of them! WayneDupree.com is proud to offer a PREMIUM VIP MEMBERSHIP that eliminates ads and gives you the BEST browsing experience.
Follow Wayne on Rumble!